- Home
- CGC vs XOMAP Comparison
CGC vs XOMAP Comparison
Compare CGC & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGC
- XOMAP
- Stock Information
- Founded
- CGC 2009
- XOMAP N/A
- Country
- CGC Canada
- XOMAP United States
- Employees
- CGC N/A
- XOMAP 13
- Industry
- CGC Pharmaceuticals and Biotechnology
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- CGC Health Care
- XOMAP Health Care
- Exchange
- CGC Nasdaq
- XOMAP Nasdaq
- Market Cap
- CGC 375.1M
- XOMAP N/A
- IPO Year
- CGC N/A
- XOMAP N/A
- Fundamental
- Price
- CGC $4.34
- XOMAP $26.24
- Analyst Decision
- CGC Sell
- XOMAP
- Analyst Count
- CGC 1
- XOMAP 0
- Target Price
- CGC $2.00
- XOMAP N/A
- AVG Volume (30 Days)
- CGC 4.0M
- XOMAP N/A
- Earning Date
- CGC 11-07-2024
- XOMAP N/A
- Dividend Yield
- CGC N/A
- XOMAP N/A
- EPS Growth
- CGC N/A
- XOMAP N/A
- EPS
- CGC N/A
- XOMAP N/A
- Revenue
- CGC $209,768,750.00
- XOMAP N/A
- Revenue This Year
- CGC N/A
- XOMAP N/A
- Revenue Next Year
- CGC $9.76
- XOMAP N/A
- P/E Ratio
- CGC N/A
- XOMAP N/A
- Revenue Growth
- CGC N/A
- XOMAP N/A
- 52 Week Low
- CGC $2.76
- XOMAP N/A
- 52 Week High
- CGC $14.92
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- CGC 44.42
- XOMAP 59.39
- Support Level
- CGC $4.06
- XOMAP $26.26
- Resistance Level
- CGC $4.51
- XOMAP $26.44
- Average True Range (ATR)
- CGC 0.19
- XOMAP 0.16
- MACD
- CGC 0.07
- XOMAP 0.02
- Stochastic Oscillator
- CGC 57.65
- XOMAP 76.68
About CGC Canopy Growth Corporation
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include skincare products under Martha Stewart CBD and Storz & Bickel vaporizers. Canopy growth merged its US assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.